先前本實驗室已經證實利用桿狀病毒/昆蟲細胞表現系統所生產出的類病毒顆粒(virus-like particles，VLP)能有效誘發體內的免疫反應，且對於多種不同株的腸病毒71型皆有良好的中和效果，顯示類病毒顆粒確實有作為腸病毒71型疫苗的潛力。在本研究中，首先我們建立類病毒顆粒穩定性檢驗分析平台，同時進行類病毒顆粒的穩定性分析，並探討能增加其穩定性的最適化條件。在第一階段的研究中，我們利用粒徑分析儀及穿透式電子顯微鏡測量與觀察類病毒顆粒的動態特性（hydrodynamic properties）。首先，我們探討不同濃度的NaCl溶液、不同種類的緩衝溶液及穩定劑對於類病毒顆粒在4□C環境下穩定性之影響，以粒徑分析儀分析類病毒顆粒的粒徑大小是否會隨著保存時間增加而變化，做為穩定性的判斷依據。而在第二階段的研究，我們採用酵素連結免疫吸附分析法分析類病毒顆粒的in-vitro antigenicity變化，評估在不同的保存條件下，類病毒顆粒隨著時間增加是否仍保持其活性，具有誘發免疫反應的能力。實驗結果顯示，類病毒顆粒的保存濃度會影響其穩定性，類病毒顆粒濃度越高，其穩定性越好，而類病毒顆粒在4□C的保存環境中，保存後第5個月後仍具有極大的穩定性，添加穩定劑對於增加類病毒顆粒穩定性並無顯著效果。此外，類病毒顆粒保存於不同的緩衝溶液中也仍具有高度的穩定性，因此在生產、純化及最後保存類病毒顆粒的製程中，我們所使用的緩衝溶液並不會影響類病毒顆粒的穩定性，進而造成生產產率上的損失以及影響純化結果。因此，保存於4□C及sodium phosphate (pH 6.5)溶液中是一個相當適合類病毒顆粒的環境，使得類病毒顆粒能維持高度的穩定性。綜合上述結果，本研究證實了在類病毒顆粒各個不同階段的的製程中，類病毒顆粒仍呈現穩定的狀態，也證實類病毒顆粒在4□C之保存環境下非常穩定，不需額外添加穩定劑以增加其穩定性。

Enterovirus 71 (EV71) is an etiologic agent responsible for seasonal epidemics of hand-foot-and-mouth disease and causes outbreaks with significant mortality in child under 5 years of age, but there is no effective vaccine for EV71. Our group has previously demonstrated that EV71 virus-like particles (VLP) produced from the baculovirus/insect cell system induce high antibody titers in animal models and protect animals from virus infection, suggesting that VLPs are a good EV71 vaccine candidate. In this study, we aimed to investigate and improve the stability of EV71 VLPs. We first established the characterization methods including Dynamic Light Scattering (DLS), Transmission Electron Microscopy (TEM) and Enzyme-Linked Immunosorbent Assay (ELISA) to evaluate the VLPs stability and further examined the parameters that influence the VLPs stability, including buffer, temperature and stabilizer. The data demonstrated that the shape, size and immunogenicity of VLPs remained stable when stored in the buffers used in the VLPs production and purification processes. The VLPs also remain stabled when upon storage in sodium phosphate buffer (pH 6.5) at 4□C for 5 months. These data collectively confirm that VLPs are reasonably stable and implicate the potentials of EV71 VLPs as a vaccine product.

誌謝 II
摘要 III
Abstract IV
目錄 V
圖表目錄 VIII
第一章 文獻回顧 1
1-1 腸病毒(Enterovirus) 71型 1
1-1-1腸病毒71型病毒學概論 1
1-1-2腸病毒71型流行病學 2
1-2 桿狀病毒/昆蟲細胞表現系統 3
1-2-1昆蟲桿狀病毒(baculovirus)簡介 3
1-2-2 昆蟲細胞 4
1-2-3 桿狀病毒表現系統的發展與應用 5
1-3腸病毒71型疫苗發展 6
1-4 類病毒顆粒 7
1-5 膠體過濾層析法 8
1-6 研究動機 9
第二章 實驗材料及方法 17
2-1 昆蟲細胞培養 17
2-2 重組桿狀病毒 17
2-2-1 重組桿狀病毒載體 17
2-2-2 重組桿狀病毒放大 17
2-2-3 終點稀釋法定量病毒效價 18
2-2-4 腸病毒71型類病毒顆粒的生產 18
2-2-5生物反應器生產腸病毒71型類病毒顆粒 18

2-3純化胞外腸病毒71型類病毒顆粒 19
2-3-1切向流過濾法濃縮細胞培養收成液 19
2-3-2膠體過濾層析法 19
2-3-3樹脂管柱層析法 20
2-4 實驗分析方法 21
2-4-1 SDS-PAGE 21
2-4-2西方點墨法 22
2-4-3酵素連結免疫吸附分析法 22
2-4-4蛋白質定量法 23
2-5 粒徑分析儀 24
2-6 穿透式電子顯微鏡 24
第三章 實驗結果與討論 26
3-1 穩定性分析平台建立及初步保存條件測試 26
3-1-1 類病毒顆粒保存濃度對其穩定性的影響 26
3-1-2 NaCl濃度對類病毒顆粒穩定性的影響 27
3-1-3 緩衝溶液種類對類病毒顆粒穩定性的影響 28
3-1-4 穩定劑對類病毒顆粒穩定性的影響 28
3-2維持類病毒顆粒穩定性之保存條件最適化 29
3-2-1 類病毒顆粒保存濃度對其穩定性的影響 30
3-2-2 NaCl濃度對類病毒顆粒穩定性的影響 30
3-2-3緩衝溶液種類對類病毒顆粒穩定性的影響 31
3-2-4 溫度對類病毒顆粒穩定性的影響 32
3-2-5 穩定劑對類病毒顆粒穩定性的影響 28
第四章 結論與未來展望 47
4-1類病毒顆粒穩定性之探討 47
4-2未來展望 48
4-2-1 類病毒顆粒長期保存之穩定性 48
4-2-2 類病毒顆粒的熱穩定性分析 48
4-2-2-1微差掃描熱卡路里計 48
4-2-2-2濁度分析 49
參考文獻 51

Acharya R, Fry E, Stuart D, Fox G, Rowlands D, Brown F. 1989. The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution. Nature 337(6209):709-16.
Ansardi DC, Porter DC, Morrow CD. 1992. Myristylation of poliovirus capsid precursor-P1 is required for assembly of subviral particles. J. Virol. 66(7):4556-4563.
Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, Mizuta K, Iwasaki T, Sata T, Wakita T, Shimizu H. 2007. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 81(17):9386-95.
Arita M, Shimizu H, Nagata N, Ami Y, Suzaki Y, Sata T, Iwasaki T, Miyamura T. 2005. Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus monkeys. J Gen Virol 86(Pt 5):1391-401.
Arnold E, Luo M, Vriend G, Rossmann MG, Palmenberg AC, Parks GD, Nicklin MJH, Wimmer E. 1987. Implications of picornavirus capsid structure for polyprotein processing. Proc. Natl. Acad. Sci. USA. 84:21-25.
Basavappa R, Syed R, Flore O, Icenogle JP, Filman DJ. 1994. Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 A resolution. Protein Sci. 3:1651-1669.
Baxt B, Morgan DO, Robertson BH, Timpone CA. 1984. Epitopes on foot-and-mouth disease virus outer capsid protein VP1 involved in neutralization and cell attachment. J. Virol. 51(2):298-305.
Blomberg J, Lycke E, Ahlfors K, Johnsson T, Wolontis S, von Zeipel G. 1974. Letter: New enterovirus type associated with epidemic of aseptic meningitis and-or hand, foot, and mouth disease. Lancet 2(7872):112.
Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM and others. 2008. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 3(1):e1501.
Caggana M, Chan P, Ramsingh A. 1993. Identification of a single amino acid residue in the capsid protein VP1 of coxsackievirus B4 that determines the virulent phenotype. J. Virol. 67(8):4797-803.
Calvez V, Pelletier I, Borzakian S, Colbere-Garapin F. 1993. Identification of a region of the poliovirus genome involved in persistent infection of HEp-2 cells. J. Virol. 67(7):4432-5.
Casal JI. 1999. Use of parvovirus-like particles for vaccination and induction of multiple immune responses. Biotechnol. Appl. Biochem. 29:141-150.
Chen HF, Chang MH, Chiang BL, Jeng ST. 2006. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 24(15):2944-51.
Chen HL, Huang JY, Chu TW, Tsai TC, Hung CM, Lin CC, Liu FC, Wang LC, Chen YJ, Lin MF and others. 2008. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 26(23):2882-9.
Chiu CH, Chu C, He CC, Lin TY. 2006. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 8(7):1671-8.
Chumakov M, Voroshilova M, Shindarov L, Lavrova I, Gracheva L, Koroleva G, Vasilenko S, Brodvarova I, Nikolova M, Gyurova S and others. 1979. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol 60(3-4):329-40.
Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC. 2008. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26(15):1855-62.
Cooper A, Shaul Y. 2005. Recombinant viral capsids as an efficient vehicle of oligonucleotide delivery into cells. Biochem Biophys Res Commun 327(4):1094-9.
Couderc T, Hogle J, Le Blay H, Horaud F, Blondel B. 1993. Molecular characterization of mouse-virulent poliovirus type 1 Mahoney mutants: involvement of residues of polypeptides VP1 and VP2 located on the inner surface of the capsid protein shell. J. Virol. 67(7):3808-17.
Crevar CJ, Ross TM. 2008. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol J 5:131.
Davis TR, Trotter KM, Granados RR, Wood HA. 1992. Baculovirus expression of alkaline phosphatase as a reporter gene for evaluation of production, glycosylation and secretion. Biotechnology (N Y) 10(10):1148-50.
Emeny RT, Wheeler CM, Jansen KU, Hunt WC, Fu TM, Smith JF, MacMullen S, Esser MT, Paliard X. 2002. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in collage-aged women with a virus-like particle vaccine. J. Virol. 76:7832-7842.
Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. 2007. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 125(1):61-8.
Fox G, Parry NR, Barnett PV, McGinn B, Rowlands DJ, Brown F. 1989. The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J. Gen. Virol. 70(Pt 3):625-637.
Fujimoto T, Chikahira M, Yoshida S, Ebira H, Hasegawa A, Totsuka A, Nishio O. 2002. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: Detection and molecular epidemiology of enterovirus 71. Microbiology and Immunology 46(9):621-627.
Galarza JM, Latham T, Cupo A. 2005. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 18(1):244-51.
Ghosh S, Parvez MK, Banerjee K, Sarin SK, Hasnain SE. 2002. Baculovirus as mammalian cell expression vector for gene therapy: an emerging strategy. Mol Ther 6(1):5-11.
Gilbert SC. 2001. Virus-like particles as vaccine adjuvants. Mol Biotechnol 19(2):169-177.
Hanecak R, Semler BL, Ariga H, Anderson CW, Wimmer E. 1984. Expression of a cloned gene segment of poliovirus in E. coli: evidence for autocatalytic production of the viral proteinase. Cell 37(3):1063-73.
Harmann CM, Schwimmbeck PL, Mertens T, Schulthesiss HP, Strauer BE. 1994. Identification of serotype-specific and nonserotype-specific B-Cell epitopes of coxsackie B virus using synthetic peptides. Virology. 200:381-389.
Ho Y, Lin PH, Liu CY, Lee SP, Chao YC. 2004. Assembly of human severe acute respiratory syndrome coronavirus-like particles. Biochem Biophys Res Commun 318(4):833-8.
Hogle JM, Chow M, Filman DJ. 1985. Three dimensional structure of poliovirus at 2.9 A resolution. Science 229:1358-1365.
Hu YC, Hsu JT, Huang JH, Ho MS, Ho YC. 2003. Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells. Biotechnol Lett 25(12):919-25.
Kalbfuss B, Wolff M, Morenweiser R, Reichl U. 2007. Purification of cell culture-derived human influenza A virus by size-exclusion and anion-exchange chromatography. Biotechnol Bioeng 96(5):932-44.
Koch F, Koch G. 1985. The molecular biology of poliovirus. Vienna: Springer-Verlag.
Krauzewicz N, Stokrova J, Jenkins C, Elliott M, Higgins CF, Griffin BE. 2000. Virus-like gene transfer into cells mediated by polyoma virus pseudocapsids. Gene Ther 7(24):2122-31.
Kunin R, Myers RJ. 1949. Exchange equilibria in anion-exchange resins: porous exchangers. Discussions of the Faraday Society 7.
Lenz P, Day PM, Pang YYS, Frye SA, Jensen PN, Lowy DR, Schiller JT. 2001. Papillomavirus-like particles induce acute activation of dendritic cells. J. Immunol. 166(9):5346-5355.
Lin YC, Wu CN, Shih SR, Ho MS. 2002. Characterization of a Vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate. Vaccine 20(19-20):2485-93.
Lindberg AM, Crowell RL, Zell R, Kandolf R, Pettersson U. 1992. Mapping of the RD phenotype of the Nancy strain of coxsackievirus B3. Virus. Res. 24(2):187-96.
Luckow V.A. SMD. 1988. Treads in the development of baculovirus expression vectors. Biotechnol. 6:47-55.
Luckow VA, Summers MD. 1988. Signals important for high-level expression of foreign genes in Autographa californica nuclear polyhedrosis virus expression vectors. Virology 167(1):56-71.
Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross TM. 2008. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26(42):5393-9.
Mateu MG. 1995. Antibody recognization of piconaviruses and escape from neutralization: a structural view. Virus Res. 38:1-24.
McMinn PC. 2002. An overview of the evolution of enterovirus 71 and its clinical and public health significance. Fems Microbiology Reviews 26(1):91-107.
Minor PD. 1992. The molecular biology of poliovaccines. J. Gen. Virol. 73:3065-3077.
Minor PD, Ferguson M, Evans DMA, Almond JW, Icenogle JP. 1986. Antigenic structure of polioviruses of serotypes 1, 2 and 3. J. Gen. Virol. 67:1283-1291.
Nagy G, Takatsy S, Kukan E, Mihaly I, Domok I. 1982. Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol 71(3):217-27.
Noad R, Roy P. 2003. Virus-like particles as immunogens. Trends Microbiol 11(9):438-44.
O'Reilly D, L M, V L. 1992. Baculovirus expression vecter: a laboratory manual. New York: W.H. Freeman and Co.
Pavio N, Buc-Caron MH, Colbere-Garapin F. 1996. Persistent poliovirus infection of human fetal brain cells. J. Virol. 70(9):6395-401.
Pilipenko EV, Maslova SV, Sinyakov AN, Agol VI. 1992. Towards identification of cis-acting elements involved in the replication of enterovirus and rhinovirus RNAs: a proposal for the existence of tRNA-like terminal structures. Nucleic. Acids. Res. 20(7):1739-45.
Porath J, Flodin P. 1959. Nature 183.
Putnak JR, Phillips BA. 1981. Picornaviral structure and assembly. Microbiol. Rev. 45:287-315.
R.D. P. 1997. Baculoviruses as expression vectors. Curr. Opin. Biotechnol. 8(5):569-572.
Ramsingh AI, Caggana M, Ronstrom S. 1995. Genetic mapping of the determinants of plaque morphology of coxsackievirus B4. Arch. Virol. 140(12):2215-26.
Reimann BY, Zell R, Kandolf R. 1991. Mapping of a neutralizing antigenic site of coxsackie B4 by construction of an antigenic chimera. J. Virol. 65:3475-3480.
Roy P. 1996. Genetically engineered particulate virus-like structures and their use as vaccine delivery systems. Intervirology 39(1-2):62-71.
Rueda P, Fominaya J, Langeveld JPM, Bruschke C, Vela C, Casal JI. 2000. Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles. Vaccine 19(7-8):726-734.
Saarinen MA, Troutner KA, Gladden SG, Mitchell-Logean CM, Murhammer DW. 1999. Recombinant protein synthesis in Trichoplusia ni BTI-Tn-5B1-4 insect cell aggregates. Biotechnol Bioeng 63(5):612-7.
Samuda GM, Chang WK, Yeung CY, Tang PS. 1987. Monoplegia caused by Enterovirus 71: an outbreak in Hong Kong. Pediatr Infect Dis J 6(2):206-8.
Schmidt NJ, Lennette EH, Ho HH. 1974. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 129(3):304-9.
Shi L, Sanyal G, Ni A, Luo Z, Doshna S, Wang B, Graham TL, Wang N, Volkin DB. 2005. Stabilization of human papillomavirus virus-like particles by non-ionic surfactants. J Pharm Sci 94(7):1538-51.
Shih SR, Ho MS, Lin KH, Wu SL, Chen YT, Wu CN, Lin TY, Chang LY, Tsao KC, Ning HC and others. 2000. Genetic analysis of enterovirus 71 isolated from fatal and non-fatal cases of hand, foot and mouth disease during an epidemic in Taiwan, 1998. Virus Research 68(2):127-136.
Shih SR, Li YS, Chiou CC, Suen PC, Lin TY, Chang LY, Huang YC, Tsao KC, Ning HC, Wu TZ and others. 2000. Expression of caspid protein VP1 for use as antigen for the diagnosis of enterovirus 71 infection. Journal of Medical Virology 61(2):228-234.
Taticek RA, Choi C, Phan SE, Palomares LA, Shuler ML. 2001. Comparison of growth and recombinant protein expression in two different insect cell lines in attached and suspension culture. Biotechnology Progress 17(4):676-684.
Touze A, Bousarghin L, Ster C, Combita AL, Roingeard P, Coursaget P. 2001. Gene transfer using human polyomavirus BK virus-like particles expressed in insect cells. Journal of General Virology 82:3005-3009.
Toyoda H, Nicklin MJ, Murray MG, Anderson CW, Dunn JJ, Studier FW, Wimmer E. 1986. A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein. Cell 45(5):761-70.
Wang K-C, Wu J-C, Chung Y-C, Ho Y-C, Chang MD-T, Hu Y-C. 2005. Baculovirus as a highly efficient gene delivery vector for the expression of hepatitis delta virus antigens in mammalian cells. Biotechnol. Bioeng. 89:464-473.
Wetz K, Habermehl KO. 1982. Specific cross-linking of capsid proteins to virus RNA by ultraviolet irradiation of poliovirus. J. Gen. Virol. 59(Pt 2):397-401.
Wickham TJ, Nemerow GR. 1993. Optimization of growth methods and recombinant oritein-production in BTI-TN-5B1-4 inscet cell using the baculovirus expression system. . Biotechnology Progress 9(1):25-30.
Wu C-s, NetLibrary I, Wu. C-s, Dekker. 1995. Handbook of size exclusion chromatography.
Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. 2001. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20(5-6):895-904.
Wu SC, Liu CC, Lian WC. 2004. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine 22(29-30):3858-64.
Ypmawong MF, Dewalt PG, Johnson VH, Lamb JG, Semler BL. 1988. Protein 3CD is the major poliovirus proteinase responsible for cleavage of the P1 capsid precursor. Virology 166(1):265-270.
Zhang H, Blake NW, Ouyang X, Pandolfino YA, Morgan-Capner P, Archard LC. 1995. A single amino acid substitution in the capsid protein VP1 of coxsackievirus B3 (CVB3) alters plaque phenotype in Vero cells but not cardiovirulence in a mouse model. Arch. Virol. 140(5):959-66.